Pacific Biosciences of California Inc
PACB
Company Profile
Business description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
Contact
1305 O’Brien Drive
Menlo ParkCA94025
USAT: +1 650 521-8000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
485
Stocks News & Analysis
stocks
Overvalued ASX share has overly ambitious profit target
We think the new profit target is aggressive and unlikely to be met.
stocks
7 undervalued US stocks that crushed earnings
Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks
Undervalued ASX share hitting on all cylinders
Strong performance across all segments in latest earnings release.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.50 | 146.90 | -1.60% |
| CAC 40 | 8,352.00 | 16.91 | -0.20% |
| DAX 40 | 26,598.64 | 151.31 | -0.57% |
| Dow JONES (US) | 51,608.17 | 739.38 | -1.41% |
| FTSE 100 | 10,881.55 | 21.01 | -0.19% |
| HKSE | 23,458.96 | 294.88 | -1.24% |
| NASDAQ | 24,509.76 | 626.52 | -2.49% |
| Nikkei 225 | 58,935.99 | 726.03 | -1.22% |
| NZX 50 Index | 14,307.63 | 3.86 | 0.03% |
| S&P 500 | 7,416.59 | 145.08 | -1.92% |
| S&P/ASX 200 | 8,902.60 | 142.10 | -1.57% |
| SSE Composite Index | 3,578.26 | 24.31 | -0.67% |